Company intelligence / Profile preview

NeuBase Therapeutics, Inc.

Pittsburgh, Pennsylvania, United Statesir.neubasetherapeutics.com ↗

Ownership: Public · NBSE
Employees: ~37
Development stage: Preclinical

Overview

NeuBase Therapeutics was developing precision genetic medicines but has halted all program development. The company announced plans for dissolution with a stakeholder meeting scheduled for May 13, 2024, due to financial difficulties. Prior to this, they had shown positive preclinical data in non-human primates and patient-derived cell lines for their PATrOL platform.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Antisense Oligonucleotide (ASO)Peptide-Nucleic Acid (PNA)Gene editing
Industry: Biotech

Drug pipeline

4 assets

NT-0100

Preclinical

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.4M
Total revenue: $0
Enterprise value: $-5.8M

Beyond the preview

Go deeper on NeuBase Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuBase Therapeutics, Inc..

Explore the full profile